#USA #New York #Securities Class Action #Merck & Co #Gardasil Sales

Merck & Co., Inc. Shareholder Advisory on Class Action

In a recent announcement, The Gross Law Firm has issued a call to shareholders of Merck & Co., Inc. (NYSE: MRK) to take action regarding significant financial losses. The firm encourages individuals who acquired shares of Merck during the specified class period from February 3, 2022, to February 3, 2025, to consider joining a class action lawsuit.

Background of the Case

The allegations stem from a situation where Merck provided investors with optimistic projections regarding its expected revenue from the sales of Gardasil, a vaccine meant to prevent certain cancers. According to the complaint, Merck's defendants had claimed they were on track to reach $11 billion in sales of the vaccine by 2030, a figure that significantly influenced share values and investor confidence.

However, the situation took a turn on February 4, 2025, when the company announced that they would halt shipments of Gardasil to China at least until midyear. This unexpected development prompted a stark revelation: the company would not fulfill the previously forecasted revenue. During earnings disclosures, Merck acknowledged difficulties in recovering demand for Gardasil in the Chinese market, which was imperative for achieving the ambitious targets they had outlined.

As a result of these disclosures, the market responded swiftly. The stock price of Merck dropped sharply from $99.79 per share at closing on February 3, 2025, to $90.74 per share the following day, marking a decline exceeding 9% within just one day. This dramatic shift prompted shareholder concerns and requests for accountability.

How to Participate in the Class Action

Shareholders who acquired shares during the specified class period and have been affected by these revelations are urged to register for participation in the class action. The deadline for registration is April 14, 2025. Registration can be done through the following link: Class Action Registration.

Moreover, once registered, shareholders will receive updates and status notifications through a dedicated portfolio monitoring service throughout the case's development.

The Role of The Gross Law Firm

The Gross Law Firm, a nationally recognized law firm specializing in class action lawsuits, aims to protect investor rights against corporate deceit and misconduct. Their commitment to ensuring transparency and ethical practices in corporate governance has established them as a trusted advocate for shareholders. The firm takes pride in representing those impacted by misleading corporate statements and is dedicated to seeking the recovery of losses incurred due to such actions.

In participation, shareholders are not obligated to pursue the role of lead plaintiff to claim their recovery, making the process inclusive. This lawsuit presents an opportunity for investors adversely affected by Merck's stock fluctuation to hold the company accountable for its commitments.

For inquiries or further information, shareholders can contact The Gross Law Firm directly at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903.

It is essential for stakeholders to act now and secure their participation in this ongoing legal matter concerning one of the industry's critical players, ensuring that their voices—and investments—are heard during this pivotal time.